ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Dynamic monitoring of serum tumor markers as prognostic factors in patients with advanced non-small-cell lung cancer treated with first-line immunotherapy: a multicenter retrospective study

Yang, Xiongwen; Xiao, Yi; Zhou, Yubin; Deng, Huiyin; Yuan, Zihao; Dong, Longyan; Lan, Jun; Hu, Hao*; Huang, Jian*; Huang, Shaohong*广东医学院; 中山大学
Therapeutic Advances in Medical Oncology2023DOI: 10.1177/17588359231206282
9阅读
引用收藏
分享

摘要

Background:To date, no specific studies have reported the use of dynamic serum tumor markers (STMs) as prognostic factors in patients with advanced non-small-cell lung cancer (NSCLC) who receive first-line immunotherapy. Therefore, it is unclear whether STMs can be used as a prognostic factor for first-line immunotherapy in advanced NSCLC.Objectives:To elucidate the role of STMs in monitoring immunotherapy response in advanced NSCLC. Patients were treated with first-line programmed cell death-1/programmed cell death ligand-1 inhibitors at four Chinese centers.Design:This was a multicenter retrospective study.Methods:Blood samples were collected at baseline and after 6-8 weeks of treatment. Computed tomography scans were used to evaluate treatment efficacy according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Post-treatment drops in STMs [Serum carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), cytokeratin fragment 19 (CYFRA21-1), carbohydrate antigen 19-9 (CA19-9), and carbohydrate antigen 125 (CA125)] were decreased > 20% (Group C) over baseline was used as cutoff level for defining a marker response. If STMs were increased by > 20% after treatment, the therapeutic effect was limited (Group A). Patients with STM changes between a 20% increase or decrease were enrolled in Group B. In univariate and multivariate stepwise Cox regression analyses, STMs and RECIST responses were analyzed for their impact on progression-free survival (PFS) and overall survival (OS).Results:The analysis included 716 patients. By multivariate analysis, CEA, NSE, CYFRA21-1, CA19-9, and CA125 (Group A versus Group B and Group A versus Group C) were associated with significant differences in PFS. Similar results were observed in the OS analysis. Similar results were observed in the adenocarcinoma subgroup analyses. In squamous cell carcinoma subgroup analyses, there was no statistical difference in PFS (p = 0.147) or OS (p = 0.068) between Group A and Group B for CA125.Conclusion:The increase and decrease in serum levels of STMs might be reliable prognostic factors for immunotherapy efficacy in NSCLC patients.

学科与关键词

关键词
immunotherapyNSCLCserum tumor markerssurvivaltumor response
相关
加载中…
  • Baseline serum tumor markers predict the survival of patients with advanced non-small cell lung cancer receiving first-line immunotherapy: a multicenter retrospective study
    Huang, Jian; Xiao, Yi; Zhou, Yubin; Deng, Huiyin; Yuan, Zihao; Dong, Longyan; Lan, Jun; Li, Xiane; Liu, Gaijiao; Hu, Hao*; Huang, Shaohong*; Yang, Xiongwen*BMC CANCER, 2023, 23(1): 812.被引 1
  • Peripheral blood markers predict immunotherapeutic efficacy in patients with advanced non-small cell lung cancer: A multicenter study
    Liu, Shuai; Zhao, Liuyuan; Zhou, Guohua*Frontiers in Genetics, 2022, 13: 1016085.被引 1
  • Early on-treatment tumor growth rate (EOT-TGR) determines treatment outcomes of advanced non-small-cell lung cancer patients treated with programmed cell death protein 1 axis inhibitor
    He, L-N; Fu, S.; Ma, H.; Chen, C.; Zhang, X.; Li, H.; Du, W.; Chen, T.; Jiang, Y.; Wang, Y.; Wang, Y.; Zhou, Y.; Lin, Z.; Yang, Y.; Huang, Y.; Zhao, H.; Fang, W.; Zhang, H.*; Zhang, L.*; Hong, S.*ESMO Open, 2022, 7(6).
查看全部 →

发表信息

论文状态
公开发表
期刊
Therapeutic Advances in Medical Oncology
发表日期
2023
卷期
第 15 卷
页码
17588359231206282
DOI
10.1177/17588359231206282
语言
ENGLISH
成果收录
SCIE
资助标注
Medical Scientific Research Foundation of Guangdong Province, China [A2022142]

作者

  • Y

    Yang, Xiongwen (第一作者)

    jiangxi canc hosp

  • X

    Xiao, Yi

    sun yat sen univ

查看全部 10 位作者收起作者
  • Z

    Zhou, Yubin

    univ hongkong · sun yat sen univ

  • D

    Deng, Huiyin

  • Y

    Yuan, Zihao

    2 · guangdong med univ

  • D

    Dong, Longyan

    2 · guangdong med univ

  • L

    Lan, Jun

  • H

    Hu, Hao (通讯)

  • H

    Huang, Jian (通讯)

    jiangxi canc hosp

  • H

    Huang, Shaohong (通讯)

    sun yat sen univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417